The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States

176Citations
Citations of this article
235Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. Methods. We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma. Results. While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. Conclusions. It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.

Cite

CITATION STYLE

APA

Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., … Peterson-Pileri, K. (2015). The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States. Clinical Infectious Diseases, 61(4), 496–502. https://doi.org/10.1093/cid/civ334

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free